Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome.

Till KJ, Allen JC, Talab F, Lin K, Allsup D, Cawkwell L, Bentley A, Ringshausen I, Duckworth AD, Pettitt AR, Kalakonda N, Slupsky JR.

Sci Rep. 2017 Dec 1;7(1):16784. doi: 10.1038/s41598-017-17021-w.

2.

Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.

Gladkikh AA, Potashnikova DM, Tatarskiy V Jr, Yastrebova M, Khamidullina A, Barteneva N, Vorobjev I.

Cancer Med. 2017 Dec;6(12):2984-2997. doi: 10.1002/cam4.1257. Epub 2017 Nov 10.

3.

MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.

Saba NS, Wong DH, Tanios G, Iyer JR, Lobelle-Rich P, Dadashian EL, Liu D, Fontan L, Flemington EK, Nichols CM, Underbayev C, Safah H, Melnick A, Wiestner A, Herman SEM.

Cancer Res. 2017 Dec 15;77(24):7038-7048. doi: 10.1158/0008-5472.CAN-17-2485. Epub 2017 Oct 9.

PMID:
28993409
4.

B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.

Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V.

Mol Cancer Res. 2017 Dec;15(12):1692-1703. doi: 10.1158/1541-7786.MCR-17-0026. Epub 2017 Aug 23.

PMID:
28835371
5.

IGHV mutational status testing in chronic lymphocytic leukemia.

Crombie J, Davids MS.

Am J Hematol. 2017 Dec;92(12):1393-1397. doi: 10.1002/ajh.24808. Epub 2017 Jul 29. Review.

PMID:
28589701
6.

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.

Rigolin GM, Formigaro L, Cavallari M, Quaglia FM, Lista E, Urso A, Guardalben E, Martinelli S, Saccenti E, Bassi C, Lupini L, Bardi MA, Volta E, Tammiso E, Melandri A, Negrini M, Cavazzini F, Cuneo A.

Oncotarget. 2017 Apr 25;8(17):28008-28020. doi: 10.18632/oncotarget.15883.

7.

Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.

Shapiro M, Herishanu Y, Katz BZ, Dezorella N, Sun C, Kay S, Polliack A, Avivi I, Wiestner A, Perry C.

Haematologica. 2017 May;102(5):874-882. doi: 10.3324/haematol.2016.148965. Epub 2017 Feb 2.

8.

Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.

Rigolin GM, Saccenti E, Bassi C, Lupini L, Quaglia FM, Cavallari M, Martinelli S, Formigaro L, Lista E, Bardi MA, Volta E, Tammiso E, Melandri A, Urso A, Cavazzini F, Negrini M, Cuneo A.

J Hematol Oncol. 2016 Sep 15;9(1):88. doi: 10.1186/s13045-016-0320-z. Erratum in: J Hematol Oncol. 2016 Sep 30;9(1):103.

9.

SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course.

Dezorella N, Katz BZ, Shapiro M, Polliack A, Perry C, Herishanu Y.

Haematologica. 2016 Dec;101(12):1553-1562. Epub 2016 Jul 21.

10.

Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion.

Xiao W, Chen WW, Sorbara L, Davies-Hill T, Pittaluga S, Raffeld M, Jaffe ES.

Hum Pathol. 2016 Sep;55:108-116. doi: 10.1016/j.humpath.2016.04.019. Epub 2016 May 14.

11.

Chronic lymphocytic leukemia: treatment of relapse.

Montillo M.

Leuk Suppl. 2012 Aug;1(Suppl 2):S31-2. doi: 10.1038/leusup.2012.18. Epub 2012 Aug 9.

12.

Prognostic factors in CLL.

Ferrarini M, Cutrona G, Neri A, Morabito F.

Leuk Suppl. 2012 Aug;1(Suppl 2):S29-30. doi: 10.1038/leusup.2012.17. Epub 2012 Aug 9.

13.

Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.

Patten PE, Ferrer G, Chen SS, Simone R, Marsilio S, Yan XJ, Gitto Z, Yuan C, Kolitz JE, Barrientos J, Allen SL, Rai KR, MacCarthy T, Chu CC, Chiorazzi N.

JCI Insight. 2016 Apr 7;1(4). pii: e86288.

14.

Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation.

Rombout A, Lust S, Offner F, Naessens E, Verhasselt B, Philippé J.

Br J Cancer. 2016 Mar 15;114(6):704-12. doi: 10.1038/bjc.2016.35. Epub 2016 Feb 25.

15.

Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia.

Yepes S, Torres MM, López-Kleine L.

BMC Genomics. 2015 Nov 25;16:1002. doi: 10.1186/s12864-015-2189-6.

16.

JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia.

Montresor A, Toffali L, Mirenda M, Rigo A, Vinante F, Laudanna C.

Oncotarget. 2015 Oct 27;6(33):34245-57. doi: 10.18632/oncotarget.5196.

17.

Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.

Ganguly S, Home T, Yacoub A, Kambhampati S, Shi H, Dandawate P, Padhye S, Saluja AK, McGuirk J, Rao R.

Oncotarget. 2015 Oct 13;6(31):31767-79. doi: 10.18632/oncotarget.5167.

18.

Cytokine Contents in Chronic Lymphocytic Leukemia: Association with ZAP70 Expression.

Işıksaçan N, Çınar S, Aktaş Çetin E, Aktan M, Deniz G.

Turk J Haematol. 2016 Sep 5;33(3):202-8. doi: 10.4274/tjh.2014.0469. Epub 2015 Aug 6.

19.

Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Ten Hacken E, Burger JA.

Biochim Biophys Acta. 2016 Mar;1863(3):401-413. doi: 10.1016/j.bbamcr.2015.07.009. Epub 2015 Jul 17. Review.

20.

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.

Bresin A, Callegari E, D'Abundo L, Cattani C, Bassi C, Zagatti B, Narducci MG, Caprini E, Pekarsky Y, Croce CM, Sabbioni S, Russo G, Negrini M.

Oncotarget. 2015 Aug 14;6(23):19807-18.

Supplemental Content

Support Center